While Onglyza was approved by the FDA in 2009 for the treatment of Type II diabetes, a 2013 study found that the medication may be linked to an increased risk of pancreatic cancer and cardiovascular complications, including heart failure.
Lawsuits filed against Onglyza claim the pharmaceutical manufacturer behind the drug failed to adequately warn of its risks, inaccurately marketed the medication and its benefits, and prioritized profit over patient safety. Patients who have suffered medical injury or complications after taking Onglyza, may be eligible to receive compensation for medical costs, lost wages, pain and suffering, wrongful death, and punitive damages.
